Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
- Dana-Farber Cancer Institute, United States
- Broad Institute of Harvard and MIT, United States
- Rare Cancer Research Foundation, United States
- RMC Support, United States
- Boston Children's Hospital, United States
- St Jude Children's Research Hospital, United States
- Dana-Farber Cancer Institue, United States
Abstract
Renal medullary carcinoma (RMC) is a rare and deadly kidney cancer in patients of African descent with sickle cell trait. We have developed faithful patient-derived RMC models and using whole-genome sequencing, we identified loss-of-function intronic fusion events in one SMARCB1 allele with concurrent loss of the other allele. Biochemical and functional characterization of these models revealed that RMC requires the loss of SMARCB1 for survival. Through integration of RNAi and CRISPR-Cas9 loss-of-function genetic screens and a small-molecule screen, we found that the ubiquitin-proteasome system (UPS) was essential in RMC. Inhibition of the UPS caused a G2/M arrest due to constitutive accumulation of cyclin B1. These observations extend across cancers that harbor SMARCB1 loss, which also require expression of the E2 ubiquitin-conjugating enzyme, UBE2C. Our studies identify a synthetic lethal relationship between SMARCB1-deficient cancers and reliance on the UPS which provides the foundation for a mechanism-informed clinical trial with proteasome inhibitors.
Data availability
Data and materials availability: Noted plasmids in the text are available through Addgene or the Genomics Perturbations Platform at the Broad Institute of Harvard and MIT. CLF_PEDS0005_T1, CLF_PEDS0005_T2B, CLF_PEDS0005_T2A and CLF_PEDS9001_T1 cell lines are available through the Cancer Cell Line Factory at the Broad Institute of Harvard and MIT. Sequencing data reported in this paper (whole-genome sequencing and whole-exome sequencing) has been deposited in the database of Genotypes and Phenotypes (dbGaP) and GEO GSE111787.
-
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibitionNCBI Gene Expression Omnibus, GSE111787.
-
Mouse Smarcb1-deficient models recapitulate subtypes of human rhabdoid tumors.NCBI Gene Expression Omnibus, GSE64019.
-
SMARCB1-deficient rhaboid tumors of the kidney and renal medullary carcinomas.NCBI Gene Expression Omnibus, GSE70421.
-
Gene expression data from ATRT tumor samplesNCBI Gene Expression Omnibus, GSE70678.
-
Expression data from the Cancer Cell Line Encyclopedia (CCLE)NCBI Gene Expression Omnibus, GSE36133.
Article and author information
Author details
Funding
National Cancer Institute (U01 CA176058)
- William C Hahn
Wong Family Award
- Andrew L Hong
American Cancer Society (132943-MRSG-18-202-01-TBG)
- Andrew L Hong
National Cancer Institute (U01 CA217848)
- Stuart L Schreiber
National Institute of General Medical Sciences (T32 GM007753)
- Thomas P Howard
National Institute of General Medical Sciences (T32 GM007226)
- Thomas P Howard
Boston Children's Hospital (OFD BTREC CDA)
- Andrew L Hong
U.S. Department of Defense (W81XWH-15-1-0659)
- Gabriel J Sandoval
National Cancer Institute (P50 CA101942)
- Andrew L Hong
Katie Moore Foundation
- Jesse S Boehm
Merkin Family Foundation
- Jesse S Boehm
American Association for Cancer Research (14-40-31-HONG)
- Andrew L Hong
CureSearch for Children's Cancer (328545)
- Andrew L Hong
Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12 HD052896)
- Andrew L Hong
Alex's Lemonade Stand Foundation for Childhood Cancer (Young Investigator Award)
- Andrew L Hong
Cure AT/RT
- Andrew L Hong
- Susan N Chi
Team Path to Cure
- Andrew L Hong
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Ethics
Animal experimentation: This research protocol (04-111) has been reviewed and approved by the Dana-Farber Cancer Institute's Animal Care and Use Committee (IACUC), in compliance with the Animal Welfare Act and the Office of Laboratory Welfare (OLAW) of the National Institutes of Health (NIH).
Human subjects: Patients assented and / or families consented to Dana-Farber Cancer Institute IRB approved protocols: 11-104, 16-031.
Copyright
© 2019, Hong et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 4,448
- views
-
- 640
- downloads
-
- 35
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Renal medullary carcinomas depend upon SMARCB1 loss and are sensitive to proteasome inhibition
eLife 8:e44161.
https://doi.org/10.7554/eLife.44161
Further reading
-
- Cancer Biology
- Chromosomes and Gene Expression
Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an intrinsic cellular pathway, nonsense-mediated decay (NMD) conceals neoantigens through the destruction of the RNA products from genes harboring truncating mutations. We developed and conducted a high-throughput screen, based on the ratiometric analysis of transcripts, to identify critical mediators of NMD in human cells. This screen implicated disruption of kinase SMG1’s phosphorylation of UPF1 as a potential disruptor of NMD. This led us to design a novel SMG1 inhibitor, KVS0001, that elevates the expression of transcripts and proteins resulting from human and murine truncating mutations in vitro and murine cells in vivo. Most importantly, KVS0001 concomitantly increased the presentation of immune-targetable human leukocyte antigens (HLA) class I-associated peptides from NMD-downregulated proteins on the surface of human cancer cells. KVS0001 provides new opportunities for studying NMD and the diseases in which NMD plays a role, including cancer and inherited diseases.
-
- Cancer Biology
For traditional laboratory microscopy observation, the multi-dimensional, real-time, in situ observation of three-dimensional (3D) tumor spheroids has always been the pain point in cell spheroid observation. In this study, we designed a side-view observation petri dish/device that reflects light, enabling in situ observation of the 3D morphology of cell spheroids using conventional inverted laboratory microscopes. We used a 3D-printed handle and frame to support a first-surface mirror, positioning the device within a cell culture petri dish to image cell spheroid samples. The imaging conditions, such as the distance between the mirror and the 3D spheroids, the light source, and the impact of the culture medium, were systematically studied to validate the in situ side-view observation. The results proved that placing the surface mirror adjacent to the spheroids enables non-destructive in situ real-time tracking of tumor spheroid formation, migration, and fusion dynamics. The correlation between spheroid thickness and dark core appearance under light microscopy and the therapeutic effects of chemotherapy doxorubicin and natural killer cells on spheroids’ 3D structure was investigated.
